Scibase AB (SCIB) - Total Assets
Based on the latest financial reports, Scibase AB (SCIB) holds total assets worth Skr103.69 Million SEK (≈ $11.16 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Scibase AB - Total Assets Trend (2012–2025)
This chart illustrates how Scibase AB's total assets have evolved over time, based on quarterly financial data. Also see Scibase AB (SCIB) total market value for the company's overall valuation and market capitalisation.
Scibase AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Scibase AB's total assets of Skr103.69 Million consist of 91.9% current assets and 8.1% non-current assets. Review Scibase AB debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr22.60 Million | 43.3% |
| Accounts Receivable | Skr16.06 Million | 30.8% |
| Inventory | Skr9.27 Million | 17.8% |
| Property, Plant & Equipment | Skr4.23 Million | 8.1% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Scibase AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Scibase AB stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scibase AB's current assets represent 91.9% of total assets in 2025, a decrease from 95.7% in 2012.
- Cash Position: Cash and equivalents constituted 43.3% of total assets in 2025, down from 74.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is cash and equivalents at 43.3% of total assets.
Scibase AB Competitors by Total Assets
Key competitors of Scibase AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
Scibase AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.15 | 3.44 | 8.38 |
| Quick Ratio | 3.74 | 2.96 | 7.76 |
| Cash Ratio | 0.00 | 2.14 | 7.29 |
| Working Capital | Skr74.86 Million | Skr39.17 Million | Skr89.33 Million |
Scibase AB - Advanced Valuation Insights
This section examines the relationship between Scibase AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.93 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -15.5% |
| Total Assets | Skr52.17 Million |
| Market Capitalization | $17.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scibase AB's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scibase AB's assets decreased by 15.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scibase AB (2012–2025)
The table below shows the annual total assets of Scibase AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr52.17 Million ≈ $5.61 Million |
-15.49% |
| 2024-12-31 | Skr61.73 Million ≈ $6.64 Million |
-4.05% |
| 2023-12-31 | Skr64.33 Million ≈ $6.92 Million |
+29.04% |
| 2022-12-31 | Skr49.85 Million ≈ $5.37 Million |
-41.66% |
| 2021-12-31 | Skr85.46 Million ≈ $9.20 Million |
+44.23% |
| 2020-12-31 | Skr59.25 Million ≈ $6.38 Million |
+28.36% |
| 2019-12-31 | Skr46.16 Million ≈ $4.97 Million |
-43.09% |
| 2018-12-31 | Skr81.11 Million ≈ $8.73 Million |
-36.59% |
| 2017-12-31 | Skr127.91 Million ≈ $13.77 Million |
+25.27% |
| 2016-12-31 | Skr102.11 Million ≈ $10.99 Million |
-33.37% |
| 2015-12-31 | Skr153.25 Million ≈ $16.49 Million |
+268.29% |
| 2014-12-31 | Skr41.61 Million ≈ $4.48 Million |
-4.73% |
| 2013-12-31 | Skr43.68 Million ≈ $4.70 Million |
+82.97% |
| 2012-12-31 | Skr23.87 Million ≈ $2.57 Million |
-- |
About Scibase AB
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin c… Read more